Eli Lilly Advances Retatrutide; Caps Senior Weight-Loss Drug Costs at $35
LLY•Eli Lilly’s investigational triple agonist retatrutide engages GLP-1, GIP and glucagon receptors to potentially exceed current weight-loss efficacy thresholds. The company also unveiled a senior-citizen prescription plan capping monthly out-of-pocket costs for its weight-loss drugs at $35 to expand Medicare patient access.
1. Retatrutide Triple Agonist Progress
Eli Lilly’s retatrutide candidate combines GLP-1, GIP and glucagon receptor agonism to drive weight reduction beyond existing GLP-1RA products. Early clinical data have indicated superior mean weight-loss percentages versus marketed therapies, positioning retatrutide as a potential new industry benchmark.
2. Senior-Citizen Pricing Program
The company launched a targeted savings program for Medicare beneficiaries, fixing monthly out-of-pocket costs for its weight-loss medications at $35. This initiative aims to broaden patient uptake, improve adherence and counter competitive discounting by rival drugmakers.
